Jinyu Bio-technology Co., Ltd.

XSSC:600201 Stock Report

Market Cap: CN¥8.0b

Jinyu Bio-technology Past Earnings Performance

Past criteria checks 1/6

Jinyu Bio-technology's earnings have been declining at an average annual rate of -6.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 3.1% per year. Jinyu Bio-technology's return on equity is 2.9%, and it has net margins of 12.2%.

Key information

-6.2%

Earnings growth rate

-5.7%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate3.1%
Return on equity2.9%
Net Margin12.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jinyu Bio-technology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600201 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,350165471122
30 Jun 241,525272479137
31 Mar 241,582283510149
31 Dec 231,598284518143
30 Sep 231,639289475155
30 Jun 231,572240461145
31 Mar 231,551236436133
31 Dec 221,529211423134
30 Sep 221,546174461158
30 Jun 221,578229462161
31 Mar 221,599252487164
31 Dec 211,776382503166
30 Sep 211,813529456142
30 Jun 211,798482454138
31 Mar 211,735467418137
31 Dec 201,582406399131
30 Sep 201,387268399111
30 Jun 201,24023435796
31 Mar 201,15921335590
31 Dec 191,12722134587
30 Sep 191,31232237791
30 Jun 191,646565389107
31 Mar 191,673617395111
31 Dec 181,897754413107
30 Sep 182,008869502106
30 Jun 181,909842476114
31 Mar 181,99790046987
31 Dec 171,90187044872
30 Sep 171,80984239642
30 Jun 171,6517484130
31 Mar 171,6357194240
31 Dec 161,5176454150
30 Sep 161,3935613770
30 Jun 161,3095183630
31 Mar 161,2525053560
31 Dec 151,2474803560
30 Sep 151,2104993280
30 Jun 151,1164363300
31 Mar 151,0634332970
31 Dec 141,0634043110
30 Sep 149213462780
30 Jun 148743082500
31 Mar 148492772310
31 Dec 136712512200

Quality Earnings: 600201 has high quality earnings.

Growing Profit Margin: 600201's current net profit margins (12.2%) are lower than last year (17.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600201's earnings have declined by 6.2% per year over the past 5 years.

Accelerating Growth: 600201's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600201 had negative earnings growth (-42.9%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 600201's Return on Equity (2.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinyu Bio-technology Co., Ltd. is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Jia ChenChangjiang Securities Co. LTD.
Fu YangChasing Securities